BONESUPPORT announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has published its proposed rule for the Medicare Inpatient Prospective Payment System (IPPS) for fiscal year 2027. The proposal includes changes that improve payments for the use of CERAMENT G in the treatment of complex orthopedic infections, such as periprosthetic joint infection, fracture-related infections, etc.
In parallel, CMS proposes the introduction of more specific procedure and identification codes for CERAMENT G and CERAMENT V, consistent with the company’s submission.
CMS also proposes New Technology Add‑on Payment (NTAP) reimbursement for CERAMENT V effective October 1, 2026, provided that FDA grants the company’s De Novo application by April 30, 2026. If FDA approval is obtained at a later point in time, the company plans to submit a new NTAP application, with the potential for additional payment from October 1, 2027.
The company intends to submit additional clarifications to CMS during the ongoing 60‑day public comment period. A final decision from CMS is expected in late summer 2026.
BONESUPPORT announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has published its proposed rule for the Medicare Inpatient Prospective Payment System (IPPS) for fiscal year 2027. The proposal includes changes that improve payments for the use of CERAMENT G in the treatment of complex orthopedic infections, such as...
BONESUPPORT announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has published its proposed rule for the Medicare Inpatient Prospective Payment System (IPPS) for fiscal year 2027. The proposal includes changes that improve payments for the use of CERAMENT G in the treatment of complex orthopedic infections, such as periprosthetic joint infection, fracture-related infections, etc.
In parallel, CMS proposes the introduction of more specific procedure and identification codes for CERAMENT G and CERAMENT V, consistent with the company’s submission.
CMS also proposes New Technology Add‑on Payment (NTAP) reimbursement for CERAMENT V effective October 1, 2026, provided that FDA grants the company’s De Novo application by April 30, 2026. If FDA approval is obtained at a later point in time, the company plans to submit a new NTAP application, with the potential for additional payment from October 1, 2027.
The company intends to submit additional clarifications to CMS during the ongoing 60‑day public comment period. A final decision from CMS is expected in late summer 2026.
Copy to clipboard 
